The Canadian POMC Genetic Obesity Drugs market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Proopiomelanocortin (POMC) is the polypeptide precursor of several biologically active melanocortin peptides that have essential roles in regulating food intake and energy homeostasis, adrenal steroidogenesis, melanocyte stimulation, and immune modulation. In 2018, 26.8% of Canadians 18 and older (roughly 7.3 million adults) reported height and weight that classified them as obese. Another 9.9 million adults (36.3%) were classified as overweight, bringing the total population with increased health risks due to excess weight to 63.1% in 2018. This increased from 2015 where 61.9% of Canadians aged 18 and older were overweight or obese. The high level of awareness among the population about obesity and the various risks arising from the medical condition increased healthcare expenditure, the presence of favourable reimbursement policies, extensive research and development activities in the field, and the increased involvement of government as well as non-government organizations in generating awareness and funding research.



Market Drivers

The increasing prevalence of POMC Genetic obesity is propelling the demand for these drugs in Canada. The growing incidence of lifestyle diseases. Obesity-linked disorders such as heart attacks, strokes, diabetes, and cancer are increasingly reported in Canada.The increasing awareness among the patient about the weight gains and associated impacts on other health disorders attracts the patients towards this medication. The growing adoption of a sedentary lifestyle and unhealthy diet plans, and the lack of exercise have led to increased body weight and adoption of POMC Genetic Obesity drugs. The lack of weight management among the people and false mindsets of the people are the two factors restraining the growth of these markets.